Review Article
Therapeutic Approaches for Peripheral and Central Neuropathic Pain

Délia Szok,1 János Tajti,1 Aliz Nyári,1 and László Vécsei1,2

1Department of Neurology, Interdisciplinary Excellence Centre, Faculty of Medicine, University of Szeged, Semmelweis u. 6, H-6725 Szeged, Hungary
2MTA-SZTE Neuroscience Research Group, Semmelweis u. 6, H-6725 Szeged, Hungary

Correspondence should be addressed to Délia Szok; szok.delia@med.u-szeged.hu

Received 18 July 2019; Revised 20 September 2019; Accepted 30 October 2019; Published 21 November 2019

Academic Editor: Luigi Trojano

Copyright © 2019 Délia Szok et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Neuropathic pain is a chronic secondary pain condition, which is a consequence of peripheral or central nervous (somatosensory) system lesions or diseases. It is a devastating condition, which affects around 7% of the general population. Numerous etiological factors contribute to the development of chronic neuropathic pain. It can originate from the peripheral part of the nervous system such as in the case of trigeminal or postherpetic neuralgia, peripheral nerve injury, painful polyneuropathies, or radiculopathies. Central chronic neuropathic pain can develop as a result of spinal cord or brain injury, stroke, or multiple sclerosis. As first-line pharmacological treatment options, tricyclic antidepressants, serotonin-norepinephrine reuptake inhibitors, and gabapentinoids are recommended. In trigeminal neuralgia, carbamazepine and oxcarbazepine are the first-choice drugs. In drug-refractory cases, interventional, physical, and psychological therapies are available. This review was structured based on a PubMed search of papers published in the field from 2010 until May 2019.

1. Introduction

The current definition of neuropathic pain (NP) was released almost one decade ago by the International Association for the Study of Pain (IASP) [1]. Based on this statement, NP is caused by a lesion or disease of the somatosensory (peripheral and/or central) nervous system. This special type of pain affects some 7-10% of the general population globally, predominantly in patients above 50 years of age [2]. The characteristics of NP are clearly distinct from those of nociceptive pain, which together represent the two fundamental groups of pain conditions. However, according to a new mixed pain concept, an additional group of pain disorders is proposed, which is referred to as “nociplastic pain” [3]. Chronic NP includes peripheral and central NP conditions [4].

A substantial advancement in this field is the latest classification of these heterogeneous pain syndromes, published by the IASP in 2019 [5]. The subtypes of chronic peripheral NP are the following: trigeminal neuralgia (TN), chronic NP after peripheral nerve injury, painful polyneuropathy, postherpetic neuralgia, and painful radiculopathy. The following forms belong to chronic central NP: chronic central NP associated with spinal cord injury (SCI), chronic central NP associated with brain injury, chronic central post-stroke pain, and chronic central NP associated with multiple sclerosis (MS) [4] (Tables 1 and 2). In general, NP conditions are underrecognized, underdiagnosed, and undertreated.

Treating NP is a real challenge for physicians. The management of NP targets predominantly the clinical symptoms instead of the causative factors. Currently available treatment options include both pharmacological and nonpharmacological approaches.

Regarding pharmacological therapies in NP, tricyclic antidepressants (TCA; e.g., amitriptyline), serotonin-norepinephrine reuptake inhibitors (SNRIs; i.e., duloxetine and venlafaxine), and gabapentinoids (i.e., gabapentin and pregabalin) are recommended as first-line treatments. In second-line, weak opioid analgesics (e.g., tramadol and tapentadol) are recommended. Topical agents (i.e., lidocaine plaster and capsaicin patch) are recommended as second-
line pharmacological treatments exclusively in peripheral NP. As third-line drugs, strong opioids (e.g., morphine and oxycodone) are recommended both in central and peripheral NP conditions, whereas botulinum toxin type A-haemagglutinin complex (BoNTA) can be recommended only in peripheral NP conditions. In TN, carbamazepine (CBZ) and oxcarbazepine (OXC) are the first-choice drugs.

Nonpharmacological therapeutic options for drug-refractory NP include the following approaches: interventional therapies (e.g., peripheral nerve blockade, epidural steroid injection, sympathetic nerve/ganglion treatment, intrathecal drug/medication delivery, and peripheral and central neurostimulation), physical therapies (e.g., massage, ultrasound, transcutaneous electrical nerve stimulation (TENS), laser, and mirror therapy exercise training), and psychological therapies (cognitive behavioural therapy (CBT), psychotherapy, and internet-delivered psychological therapies).

Papers selected for this work were searched by PubMed with the keywords: “peripheral neuropathic pain”, “central neuropathic pain”, “trigeminal neuralgia”, “chronic neuropathic pain after peripheral nerve injury”, “painful polyneuropathy”, “postherpetic neuralgia”, “painful radiculopathy”, “chronic central neuropathic pain associated with spinal cord injury”, “chronic central neuropathic pain associated with brain injury”, “chronic central post-stroke pain”, or “chronic central neuropathic pain associated with multiple sclerosis” and “therapy”, “treatment”, “pharmacological”, “non-pharmacological”, “investigational therapy”, “physical therapy”, or “psychological therapy”. Only abstracts published in English were considered. The PubMed search was done for papers published from 2010 until May 2019.

The aim of this review was to provide an expert view summarizing the current status of available therapeutic possibilities both in peripheral and central NP conditions, based on the novel IASP classification system of chronic NP conditions. An additional goal was to present the results of the clinical trials of nonpharmacological approaches in different types of drug-refractory NP.

2. Chronic Peripheral NP

2.1. Trigeminal Neuralgia. According to the new concept of classification of chronic pain by the IASP, TN is classified as a subclass of “chronic peripheral NP”; however, it has “chronic secondary headaches and orofacial pains” as an additional parent [4].

The definition of TN is based on the diagnostic criteria of the latest classification of the International Headache Society (ICHD-3) [6, 7]. This is a devastating pain condition characterized by recurrent unilateral orofacial ache restricted to one or more branches of the trigeminal nerve. The characteristics of the pain can be described as electric shock-like, shooting, stabbing, or sharp in quality and severe in intensity. The painful attacks last from a couple of seconds to a maximum 2 minutes. This painful paroxysm can be triggered by innocuous mechanical stimuli or orofacial movements. Even more, in some cases, involuntary painful contractions of the muscles on the face can occur, as it was referred to by the previous term “tic douloureux.”

TN is a subtype of painful cranial neuropathies and is divided to classical, secondary, and idiopathic forms. Painful trigeminal neuropathy is classified as a different entity [6–8]. The essence of classical TN is that the patients have

---

| Table 1: The IASP classification of chronic pain [35]. |
|------------------------------------------------------|
| Chronic pain                                         |
| Chronic primary pain syndromes                       |
| Chronic widespread pain                              |
| Complex regional pain syndrome                       |
| Chronic primary headache or orofacial pain           |
| Chronic primary visceral pain                        |
| Chronic primary musculoskeletal pain                 |
| Chronic secondary pain syndromes                     |
| Chronic cancer-related pain                          |
| Chronic postsurgical or posttraumatic pain           |
| Chronic NP                                          |
| Chronic secondary headache or orofacial pain         |
| Chronic secondary visceral pain                       |
| Chronic secondary musculoskeletal pain               |

Abbreviation: NP = neuropathic pain.

| Table 2: The IASP classification of chronic NP [4]. |
|------------------------------------------------------|
| Chronic neuropathic pain                             |
| Chronic peripheral neuropathic pain                  |
| Trigeminal neuralgia                                 |
| Chronic NP after peripheral nerve injury             |
| Painful polyneuropathy                               |
| Postherpetic neuralgia                               |
| Painful radiculopathy                               |
| Chronic central neuropathic pain                     |
| Chronic central NP associated with spinal cord injury|
| Chronic central NP associated with brain injury      |
| Chronic central poststroke pain                      |
| Chronic central NP associated with multiple sclerosis|

Abbreviation: NP = neuropathic pain.
microvascular compression with morphological changes (nerve atrophy or displacement) of the trigeminal nerve root entry in the pons, as demonstrated by high-resolution 3T MRI [6, 7]. This subtype of TN represents some 80% of the all TN patients [9]. Secondary TN can be caused by various neurological disorders, such as tumours in the cerebellopontine angle, MS (i.e., demyelinating lesion in the pons), or an arteriovenous malformation. Clinically, the main difference between the classical and the secondary TN is that secondary TN presents with sensory abnormalities in the orofacial area innervated by the trigeminal nerve [6, 7, 10]. The last category of TN is idiopathic, which means unknown cause (i.e., proper diagnostic work-up does not confirm any lesion or disease as causative) [6, 7]. Idiopathic TN makes up about 11% of all TN cases [7].

The incidence of TN is from 4.3 to 27 cases per 100,000 capita per year and is more common in persons older than 60 years. Regarding the sex, TN is more frequent in women (5.9/100,000 cases per year) than in men (3.4/100,000 cases per year) [9].

The diagnosis of TN requires proper medical history. As regards neurological physical examination, it should be underlined that this type of pain can be triggered and in the classical form, sensory disturbances are usually absent. As for instrumental investigation, the fundamental method is high-resolution 3T MRI, which gives us information about the status of the posterior cranial fossa. The differential diagnosis of TN includes other cranial neuralgias (e.g., glossopharyngeal neuralgia), other facial pains (e.g., persistent idiopathic facial pain), primary headache disorders (such as cluster headache or other trigeminal autonomic cephalgias), and odontogenic diseases such as cracked tooth, caries, or pulpitis [11].

Treatment options of TN can be divided into a pharmacological and a surgical part. Pharmacological therapy includes CBZ, OXC, lamotrigine, pregabalin, gabapentin, baclofen, or BoNTA injection [8, 11]. Pharmacological treatment recommendations are similar in the classical and secondary forms of TN. Among these pharmacons, CBZ and OXC (as sodium ion channel blocker antiepileptics) as gold standards have strong recommendations as first-line and long-term treatment for TN [8, 11, 12]. The recommended daily dose is 200–400 mg for CBZ and 300–600 mg for OXC [13]. The majority (90%) of TN patients responds well to these drugs [7]. The number needed to treat (NNT) for CBZ is low (NNT = 1.7) [11]. Contrarily, the number needed to harm (NNH) for CBZ is high (NNH = 24 for severe side effects and NNT = 3.4 for minor side effects) [11]. The most common adverse events of CBZ are somnolence, dizziness, drowsiness, rash, liver damage, hyponatraemia, tremor, and ataxia [8, 11]. For TN patients who cannot tolerate the recommended full dose of CBZ or OXC, an add-on treatment with lamotrigine or baclofen can be advised [14]. BoNTA represents a third-line treatment option for treating TN [2, 8].

Surgical therapeutic possibilities include microvascular decompression (MVD), gamma knife radiosurgery, glycerol rhizolysis, internal neurolysis, and radiofrequency thermo coagulation. MVD is the first choice for drug-refractory TN patients with neurovascular contact. Around 73% of patients still report significant pain relief five years after MVD treatment [11].

2.2. Chronic NP after Peripheral Nerve Injury. This type of pain originates from peripheral nerve lesions and can be recurrent or persistent [4]. Based on the latest classification, “chronic NP after peripheral nerve injury” is a third-level diagnosis of the “chronic NP” group and can also be derived from “chronic posttraumatic pain,” an additional parent [4, 15]. In addition, many disorders listed in the “chronic postsurgical pain” category can be associated with neuropathic component.

2.2.1. Chronic Postsurgical Pain Disorders with Neuropathic Component. Chronic postsurgical pain develops after a surgical procedure. Disorders related to this special pain type are the following: chronic pain after amputation, chronic pain after spinal surgery, chronic pain after thoracotomy, chronic pain after breast surgery, chronic pain after herniotomy, chronic pain after hysterectomy, and chronic pain after arthroplasty [15]. Most of these conditions associate with neuropathic components in about half of the patients, which is reflected also by their therapeutic options.

(1) Chronic Pain after Amputation. By definition, chronic pain after amputation means that the pain developed after surgical amputation of a body part (e.g., limb, breast, tongue, teeth, genitalia, eye, or rectum) [15]. The most common localization of chronic pain after amputation is the distal part of the amputated limb (i.e., stump or phantom limb pain). The prevalence of phantom limb pain is between 30 and 85% [16, 17]. Pharmacological treatment of phantom limb pain is still unresolved, based on a recent Cochrane metaanalysis [18]. The suggested pharmacons are N-methyl-D-aspartate (NMDA)-receptor antagonists (e.g., ketamine and memantine), gabapentinoids (i.e., gabapentin and pregabalin), TCAs (e.g., amitriptyline), and opioids [18, 19].

(2) Chronic Pain after Spinal Surgery (Failed Back Surgery Syndrome (FBSS)). The location of this type of pain is the site of the operation or it can radiate to the lower extremities with neuropathic component [15, 20]. This chronic NP develops in an average of 20% of patient who underwent lumbar spinal surgery [15]. From therapeutic perspective, nonsteroidal anti-inflammatory drugs (NSAIDs) have only limited effect; however, the efficacy of gabapentin or pregabalin has already been proved in this type of chronic pain [20]. CBST-based treatment has also been reported to decrease postsurgical pain intensity [21]. In addition, spinal cord stimulation, as a nonpharmacological treatment option, has shown beneficial results as well [7, 20].

(3) Chronic Pain after Thoracotomy. It is defined as a pain after surgical incision to the chest wall. The prevalence of this type of chronic pain is about 50% of postthoracotomy patients, whereas about one-third develops neuropathic component as well. Optimal preemptive analgesia may give a chance to reduce this high rate [22]. As pharmacological treatment, gabapentin and pregabalin have shown a
beneficial effect. As nonpharmacological treatment, neuraxial blockade or continuous paravertebral or epidural catheter can also be used [22].

(4) Chronic Pain after Breast Surgery. Surgical procedures in the breast area lead to the development of chronic pain in some 25-60% of the cases [15]. From pharmacological point of view, amitriptyline, gabapentinoids, venlafaxine, and topical capsaicin cream, whereas as a surgical method, autologous fat grafting have shown a significant effect in pain alleviation [23, 24].

(5) Chronic Pain after Herniotomy. This type of chronic pain originates from the surgical repair of an inguinal or femoral hernia. Around 20-30% of the operated patients develop chronic pain, and some 80% of these cases suffer from neuropathic pain [15]. The treatment of postherniotomy chronic pain is not yet solved. Based on a systematic review, pulsed radiofrequency ablation as an invasive pain treatment technique can relieve chronic postherniotomy pain [25].

(6) Chronic Pain after Hysterectomy. It can occur after the surgical (open transabdominal, laparoscopic, or transvaginal) removal of the uterus and the annexes. This type of chronic pain affects 5-32% of the operated women, with neuropathic component being present in 5-50% of the cases [15, 26]. Underlying the relevance of this condition, it is estimated that 1 out of 9 women undergoes hysterectomy in the USA [27]. Proper acute pain management during and after hysterectomy may influence the development of this postsurgical chronic pain [28].

(7) Chronic Pain after Arthroplasty. Following surgical replacement of a knee or hip joint, chronic NP develops in some 27-38% of the operated patients [15]. Novel surgical techniques and adequate perioperative pain management give a chance to reduce the risk of the development chronic pain after knee arthroplasty [29]. A multimodal approach of perioperative pharmacological management includes the administration of NSAIDs, acetaminophen, corticosteroids, clonidine, ketamine, gabapentin, or pregabalin [29, 30].

2.2.2. Chronic Posttraumatic Pain Disorders with Neuropathic Component. These types of pain disorders develop after traumatic or burn injury of tissues, in particular, chronic pain after burn injury, chronic pain after peripheral or central nervous system injury, whiplash injury-associated pain, and chronic pain after musculoskeletal injury. After polytrauma, the frequency of the development of chronic pain is 46-85% [15]. In the treatment of this painful condition, pregabalin has shown strong efficacy, according to the latest Cochrane Database conclusion [31].

(1) Chronic Pain after Burn Injury. The background of this pain condition is multicausal (heat, cold, electricity, chemical, friction, or radiation injuries). Its prevalence is around 18-52% [15]. Neither pharmacological nor nonpharmacological therapies are well established [32]. A recently published retrospective cohort study concluded that early gabapentin administration for chronic pain after burn injury did not significantly diminish the pain intensity [33]. In the treatment of complex regional pain syndrome (CRPS), a condition caused by scarring after burn injury, the administration of calcitonin, bisphosphonates, mirror visual feedback treatment, and sympathetic ganglion blockade can be recommended with high levels of evidence [34]. CRPS can also result from trauma of the extremities. There are two subtypes: CRPS I and II. In CRPS I, there is no peripheral nerve injury, whereas in CRPS II, peripheral nerve injury is required for the diagnosis [35].

(2) Chronic Pain after Peripheral Nerve Injury. In addition to be a subclass of “chronic posttraumatic pain” [15], a subgroup of this condition that is associated with NP, i.e., “chronic NP after peripheral nerve injury” is in fact the parent of all pain conditions that are associated with peripheral NP, due to the novel multiple parenting classification system [4]. TCAs were found efficient in the treatment of this subtype of chronic pain [36]. In a case series of patients with therapy-resistant brachial plexus lesion that leads to chronic posttraumatic NP, peripheral nerve stimulation was effective [37].

2.3. Painful Polyneuropathy. Painful polyneuropathy is one of the most common chronic NP conditions. It is a heterogeneous group of NP and can be divided into diabetic and nondiabetic groups (including nondiabetic metabolic, autoimmune, infective (especially due to Human Immuno-deficiency Virus (HIV) infection), toxic, genetic, and drug-induced) [4].

Based on data from epidemiological studies, the prevalence of painful diabetic polyneuropathy (PDP) is variable, ranging from 14.1% to 65.3% [38]. Due to its high frequency, PDP was the prototype disorder for the development of anti-NP therapeutic strategies. The first-line drugs in PDP as recommended by different international therapeutic guidelines are the following: duloxetine, gabapentin, pregabalin, TCAs (amitriptyline), and venlafaxine ER (extended release) [12, 39, 40]. Cochrane meta-analyses concluded that gabapentin, pregabalin, and duloxetine are effective for pain relief in PDP [31, 41, 42]. The second-line recommended pharmacons are opioids [12] and capsaicin (8%) patch [2]. The high-concentration (8%) capsaicin patch provided better pain relief than that with a substantially lower concentration in PDP patients [31]. BoNTA injection is recommended as a third-line treatment in PDP [2]. As regards OXC, a Cochrane meta-analysis concluded that it had little evidence for effectiveness in PDP [43]. Similarly, a systematic analysis demonstrated that oxycodone had only very low-quality evidence to be effective in PDP [44].

As a nondiabetic painful polyneuropathy, the prevalence of HIV-related painful neuropathy is around 35% in HIV-positive patients and it is up to 50% of patients with Acquired Immune Deficiency Syndrome (AIDS) [17]. In the treatment of HIV-associated painful neuropathy, topical capsaicin (8%) patch is recommended as first-line pharmacological therapy [12]. A recent Cochrane review analysing the efficacy of pregabalin in HIV-related neuropathy revealed ineffectiveness
3. Chronic Central NP

Chronic central NP is caused by a lesion or disease of the central somatosensory nervous system. It can be related to spinal cord or brain injury, stroke, or MS [4].

3.1. Chronic Central NP Associated with SCI. By definition, chronic central NP associated with SCI is caused by a lesion or disease of the somatosensory pathway in the spinal cord [4]. This condition can also be derived from the “chronic pain after spinal cord injury” category, referring to patients who have neuropathic component as well [15].

The prevalence of chronic pain after SCI is estimated to be between 40% and 70% [17]. Reflecting the high rate of patient with NP within this group, first-line pharmacological treatments recommended by the European therapeutic guideline for chronic pain after SCI include drugs with antineuropathic potential, such as gabapentin, pregabalin, and TCAs [12, 36]. A randomized, double-blind, placebo-controlled trial (n = 40 patients) revealed that BoNTA injection was effective in pain relief compared to placebo in intractable chronic NP in patients after SCI [54, 55]. Regarding nonpharmacological interventions, exercise programme led to mean reduction in pain intensity, whereas repetitive transcranial magnetic stimulation (rTMS), acupuncture, self-hypnosis, TENS, and CBT provided no evidence of efficacy in alleviating SCI-related chronic pain. Overall, based on the data of clinical trials, evidence regarding the efficacy of nonpharmacological treatments in chronic pain after SCI is not sufficient [56].

3.2. Chronic Central NP Associated with Brain Injury. By definition, chronic central NP associated with brain injury is caused by a lesion or disease of the somatosensory areas of the brain [4]. This pain condition can also be derived from “chronic pain after brain injury” category, referring to patients with neuropathic component [15].

The estimated global yearly incidence of traumatic brain injury (TBI) is 106/100,000 capita, whereas it is around 600/100,000 capita in the case of mild TBI [57, 58]. Some 13 million people is estimated to live with disabilities related to TBI in Europe and the USA [59]. The most common pain type related to mild TBI is headache, with a prevalence of 57.8%. Other frequent pain forms include neck or back pain and musculoskeletal pain [60].

Effective pain treatment after TBI may reduce the risk for pain chronicification. For TBI-related chronic pain, topical agents, opioids (e.g., tramadol), anticonvulsants (gabapentin and pregabalin), and TCAs are recommended. Nerve blockades and epidural steroid administration may also be useful [61]. Patients with mild TBI who were treated with rTMS demonstrated significantly diminished pain intensity (as estimated by Numerical Rating Scale (NRS) and elevated physical and mental item scores of the Short-Form- (SF-) 36 questionnaire compared to the control group) [62]. Psychological distress and posttraumatic stress are often associated with TBI-related chronic pain. Different psychotherapeutic methods can be beneficial. In addition, long-term rehabilitation should be offered for these patients [63].

3.3. Chronic Central Poststroke Pain (CPSP). Poststroke pain involves neuropathic and nociceptive mechanisms. The neuropathic mechanism occurs in patients who have thalamic or parietal lobe vascular lesion predominantly in the right hemisphere [4, 64]. The prevalence of CPSP is estimated to be between 8% and 30%, with a predominance in young stroke patients (being twice as frequent as in older patients) [17, 64, 65]. Typical features of CPSP are constant or intermittent pain, hyperalgesia, and allodynia [64, 66].
Treating CPSP is a big challenge for physicians. Management of CPSP includes both pharmacological and nonpharmacological treatment options. The analyses of the efficacy of pharmacological treatments in CPSP concluded that TCAs (amitriptyline) may have some beneficial effect. The effectiveness of antiepileptics (such as CBZ, gabapentin, lamotrigine, levetiracetam, or pregabalin) in the treatment of CPSP is still highly questionable. The above drugs can also be used in combinations. The role of opioids and anaesthetics in the management of CPSP is still under debate [64–67].

Nonpharmacological treatment in CPSP includes neurostimulatory techniques (such as motor cortex stimulation, deep brain stimulation (DBS), rTMS, and psychotherapy (e.g., CBT)). The data of these therapeutic approaches is still inconclusive due to the lack of well-designed RCTs [64–67]. Until now, the main limitation of motor cortex stimulation is the relatively low number of the treated patients. In addition, the efficacy of motor cortex stimulation depends on the accurate placement of the stimulation electrode. The findings regarding the effect of DBS in CPSP patients are also variable [64–67]. The results about the effectiveness of rTMS in CPSP are disappointing [64–67].

Overall, there is no clear evidence about the efficacy of either pharmacological or nonpharmacological therapeutic options in CPSP patients.

4.1. Pharmacological Therapeutic Options for NP. The therapeutic drug regimen for NP includes TCAs, SNRIs, antiepileptics, opioid analgesics, topical agents, and other drugs. We give the quality of evidence and the strength of recommendation of these drugs based on the Grading of Recommendation, Assessment, Development and Evaluation (GRADE) system [74] (Table 3).

4.1.1. First-Line Pharmacological Treatments for NP. Among TCAs, amitriptyline (10-150 mg/day) is recommended as a first-line drug in the treatment of all NP conditions with strong recommendation based on moderate quality of evidence [2, 12, 13, 36, 74, 75]. Its major side effects are related to its anticholinergic effects (i.e., dry mouth, constipation, urinary retention, and orthostatic hypotension) [17, 36].

From the wide group of antiepileptics, gabapentinoids, such as gabapentin/gabapentin ER/enacarbil (1200-3600 mg/day/day bid) and pregabalin (300-600 mg/day bid), are the first-choice drugs in the treatment of all types of NP with strong recommendation based on high quality of evidence [2, 12, 13, 36, 74]. Regarding the latest Cochrane conclusion, the evidence for the efficacy of pregabalin in central NP is insufficient [31]. The major side effects of gabapentinoids are dizziness, sedation, and peripheral swelling [17, 36].

CBZ (200-400 mg/day) and OXC (300-600 mg/day) are recommended for TN [12, 76].

From the SNRI group, venlafaxine (150-225 mg/day once a day) and duloxetine (60-120 mg/day once a day) are the first-choice drugs with strong recommendation based on high quality of evidence for all NP conditions [2, 12, 13, 36, 74]. The most common side effect of SNRIs is nausea [17, 36].

4.1.2. Second-Line Drug Treatments for NP. The opioid analgesics tramadol/tramadol ER (200-400 mg/day bid) and tapentadol (50-600 mg/day) are second-choice drugs with weak recommendation based on moderate quality of evidence for all types of NP [2, 12, 13, 36, 74]. The most common side effects of opioids are nausea, vomiting, and constipation [36].

Regarding topical agents, lidocaine (5%) plaster and capsaicin (8%) patch are recommended as second-choice drugs in the treatment of peripheral NP. Lidocaine patches have weak recommendation based on low quality of evidence, whereas capsaicin patches have weak recommendation based on high quality of evidence in the case of peripheral NP. [2, 12, 13, 36, 74]. The main side effects of these topical agents are erythema and itching [36].

4.1.3. Third-Line Drug Treatments for NP. The strong opioids, morphine (10-120 mg/day) and oxycodone (10-120 mg/day), are recommended as third-line pharmacotherapeutic options with weak recommendation based on moderate quality of evidence for all NP conditions. The neurotoxin, BoNTA subcutaneously (50-200 IU BoNTA in 0.9% saline every three months), is a third-choice treatment option with weak recommendation based on low quality of evidence.
evidence for peripheral NP [2, 12, 13, 36, 74]. The main side effect of BoNTA treatment is pain at injection site [36].

4.1.4. Other Therapeutic Options in the Pharmacological Treatment of NP. The role of cannabis-based medicines (herbal cannabis, plant-derived, or synthetic THC or THC/CBD oromucosal spray) in chronic NP conditions has not yet been established, as their potential benefits and harms are not clear [77]. Oromucosal cannabinoids might have a beneficial effect in MS-related central NP and in peripheral NP with allodynia [2]. The effect of herbal medicinal products (e.g., nutmeg or St. John’s wort) is still controversial according to a recent Cochrane review [78].

4.2. Nonpharmacological Therapeutic Options for NP. This category includes interventional, physical, and psychological therapies.

4.2.1. Interventional Therapies for NP. Interventional treatments in different types of NP management include nerve blockades, epidural steroid injections, radiofrequency neuroablation, and intrathecal drug delivery as minimally invasive procedures, and peripheral and central neurostimulatory techniques (Table 4). Interventional treatments are indicated in intractable NP cases.

1) Peripheral Nerve Blockades. The target of peripheral nerve blockades varies, depending on the affected peripheral nerves. The injected medications are local anaesthetics or their combination with opioids, clonidine, or steroids. The efficacy of peripheral nerve blockades in NP is still inconclusive [2, 79, 80].

2) Epidural Steroid Injection. The efficacy of epidural corticosteroid (e.g., methylprednisolone, triamcinolone,
Table 4: Nonpharmacological therapeutic options for neuropathic pain.

| Interventional therapies | Indications | Comments | Ref. |
|--------------------------|-------------|----------|------|
| Nerve blockade           | Drug-refractory NP | Local anaesthetics or combination with opioids, clonidine, or steroids; inconclusive recommendation | [2, 79, 80] |
| Epidural corticosteroid injection | Drug-refractory painful radiculopathy | Methylprednisolone, triamcinolone, betamethasone, dexamethasone; moderate quality of evidence; weak strength of recommendation | [2, 79, 80] |
| Sympathetic nerve/ganglion treatment | Intractable NP | Blockade, neurolysis, or neuroablation | [2, 79–81] |
| Intrathecal drug delivery | Drug-resistant NP | Morphine, ziconotide | [2, 80, 82, 83] |
| Peripheral nerve/field stimulation | Intractable low back pain | Subcutaneous application | [84–87] |
| Transcutaneous electrical nerve stimulation (TENS) | Intractable NP | Very low level of evidence | [87–89] |
| Dorsal root ganglion stimulation | Drug-refractory CRPS and causalgia of the lower limb | High level of evidence | [87, 91] |
| Spinal cord stimulation (SCS) | Drug-refractory painful diabetic neuropathy, truncal PHN, SCI-associated NP, CPSP, FBSS with radiculopathy, CRPS I and II | Weak recommendation | [80, 87, 92] |
| Epidural motor cortex stimulation | Intractable NP | Weak recommendation | [87, 92] |
| Repetitive transcranial magnetic stimulation (rTMS) of the primary motor cortex | Intractable NP | Weak recommendation | [87, 92] |
| Transcranial direct current stimulation (tDCS) of the primary motor cortex | Intractable NP | Weak recommendation | [87, 92] |
| Deep brain stimulation (DBS); repetitive transcranial magnetic stimulation (rTMS) of the dorsolateral prefrontal cortex; transcranial direct current stimulation (tDCS) of the dorsolateral prefrontal cortex | Intractable NP | Inconclusive | [87, 92] |
| Transcranial direct current stimulation (tDCS) of the primary motor cortex | Intractable spinal cord injury-associated NP | Inconclusive | [87, 92] |

Physical therapies

| Heat and cold applications, fluidotherapy, whirlpool, massage, ultrasound, short-wave diathermy, low-frequency currents (e.g., TENS, diadynamic currents and interferential currents), high-voltage galvanic stimulation, laser | Spinal cord injury-associated NP, chronic postsurgical pain, painful radiculopathies, and painful diabetic neuropathy | Inconclusive | [93] |
| Rehabilitation techniques (relaxation techniques, acupuncture, mirror therapy, graded motor imagery, visual illusion) | Spinal cord injury-associated NP, phantom pain, CRPS, and chronic poststroke NP | Not well-established | [2, 93] |
| Exercise training | All types of NP | Beneficial effect | [94] |
betamethasone, or dexamethasone) injection for the treatment of painful radiculopathy is still debated, with the strength of recommendations ranging from weak to strong, and the quality of evidence is moderate [2, 79, 80]. Further studies are needed to clarify these inconsistent findings.

(3) Sympathetic Nerve or Ganglion Treatments. Sympathetic nerve or ganglion treatments can be performed by means of blockade, neurolysis, or ablation. The strength of recommendation of the sympathetic nerve block in the treatment of CRPS is inconclusive, and the quality of evidence is low. In truncal PHN, the strength of recommendation for sympathetic nerve blockades is against and the quality of evidence is moderate [2, 79–81].

(4) Intrathecal Drug Delivery. To date, only two medications (morphine and ziconotide) are applicable as intrathecal pain therapies for different types of chronic NP (e.g., truncal PHN, PDN, SCI, FBSS with radiculopathy, and CRPS). Well-designed clinical trials are still lacking. The strength of the recommendations in all of them is inconclusive, and the quality of evidences is low [2, 80, 82, 83].

(5) Neurostimulation. Neurostimulation is a nonpharmacological technique for the alleviation of NP. It can be divided into peripheral or central, and noninvasive or invasive neurostimulatory techniques. In the past years, several clinical studies have been published in this field. The diverse results of these studies have been evaluated by the GRADE system [2, 80, 82, 83].

(a) Peripheral Neurostimulation

(i) Peripheral Nerve/Field Stimulation. Peripheral nerve/field stimulation (subcutaneous) was effective in chronic and intractable low back pain [84–87]

(ii) TENS. The Cochrane systematic analyses concluded that the quality of evidence regarding the usefulness of TENS in the treatment of NP is very low [87–89]

(iii) Dorsal root ganglion (DRG) stimulation. A long-term, one-year outcome study revealed that DRG stimulation was effective in chronic NP; the pain was diminished by 56% at 12 months after the implantation of the leads [90]. A recent literature review has reported that the usefulness of DRG stimulation is supported by a high level of evidence. DRG stimulation was superior to spinal cord stimulation (SCS) in alleviating NP in CRPS and causalgia of the lower limb [87, 91]

(b) Central Neurostimulation. As regards the usefulness of central neurostimulatory techniques in intractable different NP conditions, weak recommendations could be established for SCS, epidural motor cortex stimulation, rTMS of primary motor cortex, and tDCS of primary motor cortex [87, 92]. Inconclusive results were found for DBS, rTMS of the dorsolateral prefrontal cortex, and tDCS of the dorsolateral prefrontal cortex in NP and for tDCS of the primary motor cortex in SCI-associated NP [87, 92]. SCS has been studied in different types of drug-refractory NP. Based on the GRADE classification, the strength of recommendations of SCS in truncal PHN, PDN, CRPS II, SCI-associated NP, and CPSP are inconclusive and quality of evidences are low. In FBSS with radiculopathy and CRPS I, the strength of recommendation for SCS is weak, and the quality of evidence is moderate [80]

4.2.2. Physical Therapies for NP. Physical therapies are optional add-on possibilities, when pharmacological treatment options do not yield not satisfactory results.

There are numerous physical therapy modalities which can be applicable in NP, including the following: heat and cold applications, fluidotherapy, whirlpool, massage, ultrasound, short-wave diathermy, low-frequency currents (such as TENS, diadynamic currents, and interferential currents), high-voltage galvanic stimulation, and laser. These
techniques have been investigated in different types of NP such as SCI, chronic postsurgical pain, radiculopathies, and PDP; however, the results are still inconclusive [93]. Regarding rehabilitation techniques of NP patients, relaxation techniques, acupuncture, mirror therapy, graded motor imagery, and visual illusion can be used in the management of different forms of NP, including SCI-associated NP, phantom pain, CRPS, and CPSP [2, 93]. Exercise training might be beneficial in the treatment of peripheral NP patients [94]. A systematic review revealed that exercise therapy combined with psychological therapy (such as mindfulness meditation, CBT, and mindfulness-based stress reduction), aerobic exercise (e.g., walking), and Thai Chi (as a strength-stability exercise) showed a moderate effect on the physical activity and quality of life in patients of PDP [95].

4.2.3. Psychological Treatments for NP. One of the main aims of psychological treatments in chronic pain conditions (including chronic NP) is to diminish the intensity of pain, distress, and disability and to improve mood. CBT, but not behavioural therapy, has a weak effect in alleviating chronic pain; it has a small effect on disability; however, it is effective in improving mood and catastrophizing outcomes [2, 96]. Internet-delivered psychological therapies in nonheadache chronic pain patients showed a tendency to reduce pain, disability, depression, and anxiety. This new method showed a similar effect to that of the conventional face-to-face psychological intervention [97]. In chronic NP conditions in adults, well-designed clinical studies of psychological treatments are lacking. Two small clinical trials on CBT and psychotherapy demonstrated insufficient evidence concerning its efficacy and safety in chronic NP [98]. In burning mouth syndrome (BMS) with neuropathic component, a chronic primary pain condition, cognitive psychotherapy has a role in the management [99]. Based on the latest Cochrane systematic review evaluating the treatment in BMS, there was no RCTs assessing psychological therapies that evaluated short-term pain relief, whereas the evidence for the efficacy of psychological therapies in BMS patients to provide long-term symptom relief is of very low quality [100]. Hypnosis was given low grades of recommendations in the treatment of chronic phantom limb pain, SCI-related NP, and MS-associated NP. The recommendation of CBT in PDP and NP associated with cancer or HIV patients was graded as a good practice point (GPP) [101].

5. Conclusion

The peripheral and central NP conditions have high prevalence and have a deep impact on the quality of life of the patients. Alleviating this devastating pain condition is challenging for healthcare professionals. The novelty of this present review is the integration of the latest IASP classification of chronic pain with the International Classification of Diseases (ICD-11), first in the literature. Overviewing the last 10 years of relevant literature, we highlight that there are no specific drugs for the treatment of either peripheral or central NP. In this field, a major improvement is that the Neuropathic Pain Special Interest Group (NeuPSIG) of the IASP has developed a grading system in order to guide drug selection for the good clinical practice. A real breakthrough regarding nonpharmacological therapeutic options for NP conditions in the last decade is that clinical trials have been conducted, meta-analyses have been published, and guidelines have been released.

In the near future, the development of personalized and NP subtype-specific treatments are needed. In intractable NP cases, invasive nonpharmacological therapeutic options can be chosen; however, further high-quality clinical trials are necessary.

Disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Acknowledgments

This work was supported by the Economic Development and Innovation Operational Program (Gazdaságfejlesztési és Innovációs Operatív Program, GINOP-2.3.2-15-2016-00034), financed by the European Union and by the MTA-SZTE Neuroscience Research Group of the Hungarian Academy of Sciences, as well as by the University of Szeged, and Ministry of Human Capacities, Hungary, grant 20391-3/2018/FEKUSTRAT. We are grateful to Levente Szalardy MD, PhD, medical proofreader, for his valuable contribution in proofreading the manuscript.

References

[1] T. S. Jensen, R. Baron, M. Haanpää et al., “A new definition of neuropathic pain,” Pain, vol. 152, no. 10. pp. 2204-2205, 2011.

[2] L. Colloca, T. Ludman, D. Bouhassira et al., “Neuropathic pain,” Nature Reviews Disease Primers, vol. 3, no. 1, article 17002, 2017.

[3] R. Freynhagen, H. A. Parada, C. A. Calderon-Ospina et al., “Current understanding of the mixed pain concept: a brief narrative review,” Current Medical Research and Opinion, vol. 35, no. 6, pp. 1011–1018, 2019.

[4] J. Scholz, N. B. Finnernup, N. Attal et al., “The IASP classification of chronic pain for ICD-11: chronic neuropathic pain,” Pain, vol. 160, no. 1, pp. 33–59, 2019.

[5] R. D. Treede, “The role of quantitative sensory testing in the prediction of chronic pain,” Pain, vol. 160, Supplement 1, pp. S66–S69, 2019.

[6] M. Arnold, “Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition,” Cephalalgia, vol. 38, no. 1, pp. 1–211, 2018.
[7] G. Cruccu, N. B. Finnerup, T. S. Jensen et al., “Trigeminal neuralgia: new classification and diagnostic grading for practice and research,” Neurology, vol. 87, no. 2, pp. 220–228, 2016.

[8] L. Bendtsen, J. M. Zakrzewska, J. Abbott et al., “European Academy of Neurology guideline on trigeminal neuralgia,” European Journal of Neurology, vol. 26, no. 6, pp. 831–849, 2019.

[9] J. R. Shafer, S. N. Khawaja, and P. F. Bavia, “Sex, gender, and orofacial pain,” Dental Clinics of North America, vol. 62, no. 4, pp. 665–682, 2018.

[10] R. Benoliel, P. Svensson, S. Evers et al., “Trigeminal neuralgia—the IASP classification of chronic pain for ICD-11: chronic secondary headache or orofacial pain,” Pain, vol. 160, no. 1, pp. 60–68, 2019.

[11] S. Maarbjerg, G. Di Stefano, L. Bendtsen, and G. Cruccu, “Trigeminal neuralgia—diagnosis and treatment,” Cephalalgia, vol. 37, no. 7, pp. 648–657, 2017.

[12] N. Attal, G. Cruccu, R. Baron et al., “EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision,” European Journal of Neurology, vol. 17, no. 9, 2010.

[13] D. Moulin, A. Boulanger, A. J. Clark et al., “Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society,” Pain Research & Management, vol. 19, no. 6, pp. 328–335, 2014.

[14] G. Di Stefano, A. Truini, and G. Cruccu, “Current and innovative pharmacological options to treat typical and atypical trigeminal neuralgia,” Drugs, vol. 78, no. 14, pp. 1433–1442, 2018.

[15] S. A. Schug, P. Lavand’homme, A. Barke, B. Korwisi, W. Rief, and R.-D. Treede, “The IASP classification of chronic pain for ICD-11,” Pain, vol. 160, no. 1, pp. 45–52, 2019.

[16] L. Nikolajsen, S. Ilkjaer, J. H. Christensen, K. Kroner, and T. S. Jensen, “Pain after amputation,” British Journal of Anaesthesia, vol. 81, no. 3, p. 486, 1998.

[17] E. Kerstman, S. Ahn, S. Battu, S. Tariq, and M. Grabois, “Neuropathic pain,” Handbook of Clinical Neurology, vol. 110, pp. 175–187, 2013.

[18] A. MJM, T. Hale, and M. Dunca, “Pharmacologic interventions for treating phantom limb pain,” The Cochrane Database of Systematic Reviews, no. 10, article CD006380, 2011.

[19] V. Wykle, J. Dennis, A. D. Beswick et al., “Systematic review of management of chronic pain after surgery,” The British Journal of Surgery, vol. 104, no. 10, pp. 1293–1306, 2017.

[20] J. H. Cho, J. H. Lee, K. S. Song, and J. Y. Hong, “Neuropathic pain after spinal surgery,” Asian Spine Journal, vol. 11, no. 4, pp. 642–652, 2017.

[21] J. L. Nicholls, M. A. Azam, L. C. Burns et al., “Psychological treatments for the management of postsurgical pain: a systematic review of randomized controlled trials,” Patient Related Outcome Measures, vol. 9, pp. 49–64, 2018.

[22] B. A. Bottiger, S. A. Esper, and M. Stafford-Smith, “Pain management strategies for thoracotomy and thoracic pain syndromes,” Seminars in Cardiothoracic and Vascular Anesthesia, vol. 18, no. 1, pp. 45–56, 2014.

[23] S. R. Humble, A. J. Dalton, and L. Li, “A systematic review of therapeutic interventions to reduce acute and chronic postsurgical pain after amputation, thoracotomy or mastectomy,” European Journal of Pain, vol. 19, no. 4, pp. 451–465, 2015.

[24] I. M. Larsson, J. Ahm Sorensen, and C. Bille, “The post-mastectomy pain syndrome—a systematic review of the treatment modalities,” The Breast Journal, vol. 23, no. 3, pp. 338–343, 2017.

[25] M. U. Werner, J. M. Bischoff, J. P. Rathmell, and H. Kehlet, “Pulsed radiofrequency in the treatment of persistent pain after inguinal herniotomy: a systematic review,” Regional Anesthesia and Pain Medicine, vol. 37, no. 3, pp. 340–343, 2012.

[26] B. Brandsborg and L. Nikolajsen, “Chronic pain after hysterectomy,” Current Opinion in Anaesthesiology, vol. 31, no. 3, pp. 268–273, 2018.

[27] E. Blanton, G. Lamvu, I. Patanwala et al., “Non-opioid pain management in benign minimally invasive hysterectomy: a systematic review,” American Journal of Obstetrics and Gynecology, vol. 216, no. 6, pp. 557–567, 2017.

[28] P. Lirk, J. Thiry, M. P. Bonnet, G. P. Joshi, F. Bonnet, and PROSPET Working Group, “Pain management after laparoscopic hysterectomy: systematic review of literature and PROSPET recommendations,” Regional Anesthesia and Pain Medicine, vol. 44, no. 4, pp. 425–436, 2019.

[29] I. Grosu, P. Lavand’homme, E. Thienpoint, “Pain after knee arthroplasty: an unresolved issue,” Knee Surgery, Sports Traumatology, Arthroscopy, vol. 22, no. 8, article 2750, pp. 1744–1758, 2014.

[30] V. I. Sakellarious, L. A. Poultsides, Y. Ma, J. Bae, S. Liu, and T. P. Sculco, “Risk assessment for chronic pain and patient satisfaction after total knee arthroplasty,” Orthopedics, vol. 39, no. 1, pp. 55–62, 2016.

[31] S. Derry, R. F. Bell, S. Straube et al., “Pregabalin for neuropathic pain in adults,” The Cochrane Database of Systematic Reviews, no. article CD007076, 2019.

[32] G. J. Summer, K. A. Puntillo, C. Miaskowski, P. G. Green, and J. D. Levine, “Burn injury pain: the continuing challenge,” The Journal of Pain, vol. 8, no. 7, pp. 533–548, 2007.

[33] C. J. Kneib, S. H. Sibbett, G. J. Carrougher, L. A. Muffley, N. S. Gibran, and S. P. Mandell, “The effects of early neuropathic pain control with gabapentin on long-term chronic pain and itch in burn patients,” Journal of Burn Care & Research, vol. 40, no. 4, pp. 457–463, 2019.

[34] S. Mewa Kinno and B. Singh, “Complex regional pain syndrome in burn pathological scarring: a case report and review of the literature,” Burns, vol. 43, no. 3, pp. e47–e52, 2017.

[35] R. D. Treede, W. Rief, A. Barke et al., “Chronic pain as a symptom or a disease: the IASP Classification of Chronic Pain for the International Classification of Diseases (ICD-11),” Pain, vol. 160, no. 1, pp. 19–27, 2019.

[36] E. Cavalli, S. Mammana, F. Nicoletti, P. Bramanti, and E. Mazzon, “The neuropathic pain: an overview of the current treatment and future therapeutic approaches,” International Journal of Immunopathology and Pharmacology, vol. 33, 2019.

[37] G. Stevanato, G. Devigili, R. Eleopra et al., “Chronic post-traumatic neuropathic pain of brachial plexus and upper limb: a new technique of peripheral nerve stimulation,” Neurosurgical Review, vol. 37, no. 3, pp. 473–480, 2014.

[38] D. Bouchassira, “Neuropathic pain: definition, assessment and epidemiology,” Revue Neurologique, vol. 175, no. 1-2, pp. 16–25, 2019.

[39] J. Tajti, D. SzoK, Z. Majlath, A. Csati, A. Petrovics-Balog, and L. Vecsei, “Alleviation of pain in painful diabetic neuropathy,” Expert Opinion on Drug Metabolism & Toxicology, vol. 12, no. 7, pp. 753–764, 2016.
[40] Z. Iqbal, S. Azmi, R. Yadav et al., “Diabetic peripheral neuropathy: epidemiology, diagnosis, and pharmacotherapy,” Clinical Therapeutics, vol. 40, no. 6, pp. 828–849, 2018.

[41] P. J. Wiffen, S. Derry, R. F. Bell et al., “Gabapentin for chronic neuropathic pain in adults,” The Cochrane Database of Systematic Reviews, no. 6, article CD007938, 2017.

[42] L. MPT, H. RAC, and P. J. Wiffen, “Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia,” The Cochrane Database of Systematic Reviews, no. 1, article CD007115, 2014.

[43] M. Zhou, N. Chen, L. He, M. Yang, C. Zhu, and F. Wu, “Oxcarbazepine for neuropathic pain,” The Cochrane Database of Systematic Reviews, no. 12, article CD007963, 2017.

[44] H. Gaskell, S. Derry, C. Stannard, and R. A. Moore, “Oxycodone for neuropathic pain in adults,” The Cochrane Database of Systematic Reviews, no. 7, article CD010692, 2016.

[45] S. Derry, A. S. Rice, P. Cole, T. Tan, and R. A. Moore, “Topical capsaicin (high concentration) for chronic neuropathic pain in adults,” The Cochrane Database of Systematic Reviews, no. 1, article CD007393, 2017.

[46] J. Schutzer-Weissmann and P. Farquhar-Smith, “Post-herpetic neuralgia - a review of current management and future directions,” Expert Opinion on Pharmacotherapy, vol. 18, no. 16, pp. 1739–1750, 2017.

[47] C. L. Romano, D. Romano, C. Bonora, and G. Mineo, “Pregabalin, celecoxib, and their combination for treatment of chronic low-back pain,” Journal of Orthopaedics and Traumatology, vol. 10, no. 4, pp. 185–191, 2009.

[48] R. Freynhagen and R. Baron, “The evaluation of neuropathic components in low back pain,” Current Pain and Headache Reports, vol. 13, no. 3, pp. 185–190, 2009.

[49] T. Andrasinova, E. Kalikova, R. Kopacik et al., “Evaluation of the neuropathic component of chronic low back pain,” The Clinical Journal of Pain, vol. 35, no. 1, pp. 7–17, 2019.

[50] M. T. Saldana, A. Navarro, C. Perez, X. Masramon, and J. Rejas, “Patient-reported-outcomes in subjects with painful lumbar or cervical radiculopathy treated with pregabalin: evidence from medical practice in primary care settings,” Rheumatology International, vol. 30, no. 8, pp. 1005–1015, 2010.

[51] S. Mathieson, C. G. Maher, A. J. McLachlan et al., “Trial of pregabalin for acute and chronic sciatica,” The New England Journal of Medicine, vol. 376, no. 12, pp. 1111–1120, 2017.

[52] E. A. Patel and M. D. Perloff, “Radicular pain syndromes: cervical, lumbar, and spinal stenosis,” Seminars in Neurology, vol. 38, no. 6, pp. 634–639, 2018.

[53] I. Urris, A. Burshtein, M. Sharma et al., “Low back pain, a comprehensive review: pathophysiology, diagnosis, and treatment,” Current Pain and Headache Reports, vol. 23, no. 3, p. 23, 2019.

[54] J. Park and M. E. Chung, “Botulinum toxin for central neuropathic pain,” Toxins, vol. 10, no. 6, p. 224, 2018.

[55] Z. A. Han, D. H. Song, H. M. Oh, and M. E. Chung, “Botulinum toxin type a for neuropathic pain in patients with spinal cord injury,” Annals of Neurology, vol. 79, no. 4, pp. 569–578, 2016.

[56] I. Boldt, I. Eriks-Hoogland, M. W. Brinkhof, R. de Bie, D. Joggi, and E. von Elm, “Non-pharmacological interventions for chronic pain in people with spinal cord injury,” The Cochrane Database of Systematic Reviews, no. 11, article CD009177, 2014.

[57] J. D. Cassidy, L. J. Carroll, P. M. Peloso et al., “Incidence, risk factors and prevention of mild traumatic brain injury: results of the WHO Collaborating Centre Task Force on Mild Traumatic Brain Injury,” Journal of Rehabilitation Medicine, vol. 36, Supplement 43, pp. 28–60, 2004.

[58] K. A. Irvine and J. D. Clark, “Chronic pain after traumatic brain injury: pathophysiology and pain mechanisms,” Pain Medicine, vol. 19, no. 7, pp. 1315–1333, 2018.

[59] N. Stocchetti, M. Carbonara, G. Citerio et al., “Severe traumatic brain injury: targeted management in the intensive care unit,” The Lancet Neurology, vol. 16, no. 6, pp. 452–467, 2017.

[60] R. Grandhi, S. Tavakoli, C. Ortega, and M. J. Simmonds, “A review of chronic pain and cognitive, mood, and motor dysfunctions following mild traumatic brain injury: complex, comorbid, and/or overlapping conditions?,” Brain Sciences, vol. 7, no. 12, p. 160, 2017.

[61] R. J. Girona, M. E. Clark, R. L. Ruff et al., “Traumatic brain injury, polytrauma, and pain: challenges and treatment strategies for the polytrauma rehabilitation,” Rehabilitation Psychology, vol. 54, no. 3, pp. 247–258, 2009.

[62] G. S. Choi, S. G. Kwak, H. D. Lee, and M. C. Chang, “Effect of high-frequency repetitive transcranial magnetic stimulation on chronic central pain after mild traumatic brain injury: a pilot study,” Journal of Rehabilitation Medicine, vol. 50, no. 3, pp. 246–252, 2018.

[63] S. Khoury and R. Benavides, “Pain with traumatic brain injury and psychological disorders,” Progress in Neuropsychopharmacology & Biological Psychiatry, vol. 87, Part B, pp. 224–233, 2018.

[64] R. A. Harrison and T. S. Field, “Post stroke pain: identification, assessment, and therapy,” Cerebrovascular Diseases, vol. 39, no. 3–4, pp. 190–201, 2015.

[65] H. Oh and W. Seo, “A comprehensive review of central post-stroke pain,” Pain Management Nursing, vol. 16, no. 5, pp. 804–818, 2015.

[66] B. Delpont, C. Blanc, G. V. Ossemy, M. Hervieu-Begue, M. Giroud, and Y. Bejot, “Pain after stroke: a review,” Revue Neurologique, vol. 174, no. 10, pp. 671–674, 2018.

[67] J. S. Kim, “Pharmacological management of central post-stroke pain: a practical guide,” CNS Drugs, vol. 28, no. 9, pp. 787–797, 2014.

[68] S. S. Duffy, J. G. Lees, C. J. Perera, and G. Moalem-Taylor, “Managing neuropathic pain in multiple sclerosis: pharmacological interventions,” Medicinal Chemistry, vol. 14, no. 2, pp. 106–119, 2018.

[69] K. L. Murphy, J. R. Bethea, and R. Fischer, “Neuropathic pain in multiple sclerosis-current therapeutic intervention and future treatment perspectives,” in Multiple Sclerosis: Perspectives in Treatment and Pathogenesis, I. S. Zagon and P. J. McLaughlin, Eds., Codon Publications, Brisbane, Australia, 2017.

[70] A. I. Fraguas-Sanchez and A. I. Torres-Suarez, “Medical use of cannabinoids,” Drugs, vol. 78, no. 16, pp. 1665–1703, 2018.

[71] J. Rice and M. Cameron, “Cannabinoids for treatment of MS symptoms: state of the evidence,” Current Neurology and Neuroscience Reports, vol. 18, no. 8, p. 50, 2018.

[72] H. Abboud, E. Hill, J. Siddiqui, A. Serra, and B. Walter, “Neuromodulation in multiple sclerosis,” Multiple Sclerosis, vol. 23, no. 13, pp. 1663–1676, 2017.

[73] B. Amatyra, J. Young, and F. Khan, “Non-pharmacological interventions for chronic pain in multiple sclerosis,” The...
**Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis**, "The Lancet Neurology," vol. 14, no. 2, pp. 162–173, 2015.

[74] N. B. Finnerup, N. Attal, S. Haroutounian et al., "Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis," *The Lancet Neurology*, vol. 14, no. 2, pp. 162–173, 2015.

[75] S. Beniczky, J. Tajti, E. Timea Varga, and L. Vecsei, "Evidence-based pharmacological treatment of neuropathic pain syndromes," *Journal of Neural Transmission*, vol. 112, no. 6, pp. 735–749, 2005.

[76] G. Cruccu and A. Truini, "A review of neuropathic pain: from guidelines to clinical practice," *Pain and therapy*, vol. 6, Supplement 1, pp. 35–42, 2017.

[77] M. Mucke, T. Phillips, L. Radbruch, F. Petzke, and W. Hauser, "Cannabis-based medicines for chronic neuropathic pain in adults," *The Cochrane Database of Systematic Reviews*, no. 3, article CD012182, 2018.

[78] A. Boyd, C. Bleakley, D. A. Hurley et al., "Herbal medicinal products and preparations for neuropathic pain," *The Cochrane Database of Systematic Reviews*, no. 4, article CD010528, 2019.

[79] A. Sdrulla and G. Chen, "Minimally invasive procedures for neuropathic pain," *Pain Management*, vol. 6, no. 2, pp. 103–109, 2016.

[80] R. H. Dworkin, A. B. O’Connor, J. Kent et al., "Interventional management of neuropathic pain: NeuPSIG recommendations," *Pain*, vol. 154, no. 11, pp. 2249–2261, 2013.

[81] R. Abramov, "Lumbar sympathetic treatment in the management of lower limb pain," *Current Pain and Headache Reports*, vol. 18, no. 4, p. 403, 2014.

[82] J. Prusik, C. Argoff, S. Peng, and J. G. Pilitsis, "Use of low dose ziconotide as first-line intrathecal monotherapy," *Neurmodulation*, vol. 20, no. 4, pp. 386–391, 2017.

[83] V. V. Sukul, "Intrathecal pain therapy for the management of chronic noncancer pain," *Neurosurgery Clinics of North America*, vol. 30, no. 2, pp. 195–201, 2019.

[84] W. P. McRoberts, R. Wolkowitz, D. J. Meyer et al., "Peripheral nerve field stimulation for the management of localized chronic intractable back pain: results from a randomized controlled study," *Neurmodulation*, vol. 16, no. 6, pp. 565–575, 2013.

[85] H. Kloimstein, R. Likar, M. Kern et al., "Peripheral nerve field stimulation (PNFS) in chronic low back pain: a prospective multicenter study," *Neurmodulation*, vol. 17, no. 2, pp. 180–187, 2014.

[86] E. A. Petersen and K. V. Slavin, "Peripheral nerve/field stimulation for chronic pain," *Neurosurgery Clinics of North America*, vol. 25, no. 4, pp. 789–797, 2014.

[87] G. Cruccu, T. Z. Aziz, L. Garcia-Larrea et al., "EFNS guidelines on neurostimulation therapy for neuropathic pain,” *European Journal of Neurology*, vol. 14, no. 9, pp. 952–970, 2007.

[88] W. Gibson, B. M. Wand, and N. E. O’Connell, "Transcutaneous electrical nerve stimulation (TENS) for neuropathic pain in adults," *The Cochrane Database of Systematic Reviews*, no. 9, article CD011976, 2017.

[89] W. Gibson, B. M. Wand, C. Meads, M. J. Catley, and N. E. O’Connell, "Transcutaneous electrical nerve stimulation (TENS) for chronic pain - an overview of Cochrane reviews,” *The Cochrane Database of Systematic Reviews*, no. 4, article CD011890, 2019.